How Cognizant aims to digitally transform the clinical trial protocol process
Cognizant has introduced Cognizant Protocol Creator, a SaaS collaboration product that supposedly automates the development of clinical trial protocol documentation. A first for the life sciences industry, Protocol Creator enables clinical teams to create and review protocol documentation in a purpose-built collaborative environment.
The software simplifies the production of protocol documents saving time and ensuring quality through the adherence to industry standards and best practices.
Taking a design-thinking approach to the development of Protocol Creator, Cognizant embedded itself with medical writing and clinical trial teams to learn about and address their challenges.
With a goal of getting a protocol to submission faster, Protocol Creator generates clinical trial documentation as a structured document. It helps teams collaborate, manage review cycles and deadlines, and enables the final protocol to be published as a traditional document or in machine-readable formats that lay the foundation for downstream automation.
Cognizant SVP Bhaskar Sambasivan says, "Bringing a single new treatment to market today costs more than a billion dollars. Every extra day spent before a protocol is approved is costly for the company and, more importantly, causes a delay in alleviating the condition of a patient who needs that treatment.
"Cognizant Protocol Creator redesigns the entire submission process to be digital first as opposed to one built around antiquated systems that were never intended for writing clinical protocols.
"Not only does it shorten the time to create the protocol and improve its quality, it lays a foundation for a fully digital lab - clinical eco-system that uses automation and artificial intelligence to improve clinical outcomes."
Cognizant Protocol Creator is the latest Life Sciences product conceived, validated and developed by Cognizant Accelerator to reach general availability. Cognizant Accelerator, the company's product and platform incubator and venture investing division, worked with Cognizant Life Sciences to bring Protocol Creator to the market.
Cognizant VP Todd Paoletti says, "We are firmly focused on delivering transformational products that adopt digital technologies to drive efficiencies throughout an organisation.
"Cognizant Protocol Creator demonstrates this focus, as it plugs a gap in the clinical trial lifecycle that has been, to date, ignored by most technology vendors. With Protocol Creator, we're underscoring our commitment to the life sciences industry as a service and product provider."
